Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading An immunohistochemical analysis of the contractile myofilaments by de Jonge, Nicolaas et al.
Left Ventricular Assist Device in
End-Stage Heart Failure: Persistence
of Structural Myocyte Damage After Unloading
An Immunohistochemical Analysis of the Contractile Myofilaments
Nicolaas de Jonge, MD,* Dick F. van Wichen, BSC,† Marguerite E. I. Schipper, MD,†
Jaap R. Lahpor, MD, PHD,* Frits H. J. Gmelig-Meyling, PHD,‡
Etienne O. Robles de Medina, MD, PHD, FACC,* Roel A. de Weger, PHD†
Utrecht, The Netherlands
OBJECTIVES We sought to evaluate the contractile proteins in cardiomyocytes of patients with end-stage
heart failure (HF) before and after mechanical support with a left ventricular assist device
(LVAD).
BACKGROUND Improvement of myocyte dysfunction has been suggested after LVAD support.
METHODS Fourteen patients’ myocardial biopsies taken at the time of LVAD implantation and after
explantation, at the time of heart transplantation, were processed for routine hematoxylin-
eosin staining and immunohistochemistry using monoclonal antibodies against actin, myosin,
tropomyosin, troponin C and T and titin. A grading scale from 1 (abnormal staining of all
myocytes, no cross-striation) to 5 (normal fiber anatomy and striation) was used. The
cross-sectional area of cardiomyocytes was also measured.
RESULTS The cardiomyocytes’ cross-sectional area decreased after support, from 519  94 m2 to
319 53 m2 (p 0.001). Actin, tropomyosin, troponin C, troponin T and titin at the time
of LVAD implantation showed widespread distortion of architecture; their grades were 1.4
0.6, 2.3  1.0, 2.1  0.9, 2.1  1.2 and 2.0  0.6, respectively. In contrast, myosin
morphology was preserved (4.6  0.7). After LVAD support, actin, tropomyosin, troponin
C, troponin T and titin showed improvement (grades 2.7  1.3 [p  0.004], 3.2  1.2 [p 
0.021], 3.3  0.9 [p  0.004], 3.0  1.1 [p  0.048] and 3.1  0.9 [p  0.001],
respectively), but no normalization. The myosin pattern deteriorated slightly (3.6  1.6 [p 
0.058]).
CONCLUSIONS After LVAD support, during a period of 213  135 days in patients with end-stage HF,
despite a decrease in the size of the cardiomyocytes, severe structural myocyte damage
persisted. This does not support complete recovery of myocyte histologic features. (J Am
Coll Cardiol 2002;39:963–9) © 2002 by the American College of Cardiology Foundation
Heart failure (HF) is a growing problem in cardiovascular
medicine. Aging of the population, prevention of premature
death by improved medical and surgical management, as
well as better therapy available for the treatment of chronic
HF, result in an increasing number of patients with this
syndrome. Heart failure may be considered a progressive
disorder, initiated after an index event that results in a
decline in the pumping capacity of the heart. It is accom-
panied by activation of neurohormonal and cytokine sys-
tems, as well as adaptive changes in the myocardium called
“remodeling” (1). This process of remodeling includes
alterations in left ventricular (LV) geometry, alterations in
extracellular matrix and alterations in the cardiomyocytes’
size, function and number. Some of the changes reported in
failing human cardiac myocytes are loss of myofilaments and
alterations in cytoskeletal proteins (2). One canine study
suggests reversibility of myocyte dysfunction, associated
with an increase in the number of contractile elements, after
treatment with beta-blockade (3). Also, in humans, revers-
ibility of myocyte dysfunction has been suggested after
mechanical support with a left ventricular assist device
(LVAD) (4–8). This raises the option to use LVAD
support as a bridge to recovery of cardiac function in
patients with end-stage HF (9–11). The number of patients
who have been weaned from the LVAD, however, is
limited, and long-term results are not available. Unloading
the heart with an LVAD will lead to a decrease in cardiac
dimensions and neurohormonal activation (5,12,13).
Whether this results in a significant and sustained reversal
of myocyte dysfunction, however, is questionable (14,15).
Few histologic studies on this subject are available (4–
6,16,17). No microscopic studies of the contractile proteins
in myocytes have been performed. The aim of this study was
to evaluate the contractile proteins in cardiomyocytes by
means of routine staining and immunohistochemical anal-
ysis of myocardial biopsies taken at the time of LVAD
implantation and to compare these with biopsies taken at
the time of heart transplantation (HTx). Furthermore, the
cardiomyocytes’ cross-sectional area before and after LVAD
support was compared.
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METHODS
Patient group. Fourteen consecutive patients (2 women
and 12 men) with refractory end-stage HF treated with a
pneumatic LVAD (Heartmate, Thoratec, Pleasanton, Cal-
ifornia) as a bridge to transplantation were included in this
study (Table 1). Eight patients had dilated cardiomyopathy
(DCM) and six had ischemic heart disease (IHD). Thirteen
patients were successfully transplanted. One patient died of
a recurrent cerebral embolism. The mean duration of LV
unloading was 213  135 days (range 71 to 455 days).
Before HTx, all patients were in New York Heart Associ-
ation functional class I and demonstrated a very good
exercise performance, as reported previously (18). All car-
diac medications had been stopped. Written, informed
consent was obtained from all patients.
Immunohistochemical analysis. Myocardial biopsy at
LVAD implantation consisted of the LV apical core re-
moved during Heartmate implantation. These biopsies were
compared with LV tissue specimens of the explanted heart
after HTx, from the apical half of the LV, outside the suture
area of the inflow cannula. In the one patient who died
before transplantation, tissue specimens of the heart at
autopsy were used. All biopsies were directly fixed in
buffered formalin, embedded in paraffin and routinely pro-
cessed for hematoxylin-eosin staining on 5-m sections.
Standard immunohistochemical analysis was performed us-
ing a three-step avidin-biotin peroxidase reaction. In brief,
the sections were deparaffinized and rehydrated, and endog-
enous peroxidase was blocked using a solution of methanol
and hydrogen peroxide. Primary antibodies were applied to
the sections for 1 h and subsequently demonstrated using a
biotinylated horse immunoglobulin G (IgG) anti-mouse
IgG and horseradish peroxidase-labeled streptavidin. Im-
munovisualization was performed using 3,3 diamino benzi-
dine tetra hydrochloride reagents and counterstaining with
Mayer’s hematoxylin. The sections were dehydrated, cleared
and embedded in Pertex mounting medium (Histolab,
Go¨teborg, Sweden). Primary monoclonal antibodies used in
this study were anti-sarcomere actin (Sigma, Zwy¨ndrecht,
The Netherlands), myosin slow (Sigma), tropomyosin (Sig-
ma), troponin T (Sigma), troponin C (Novocastra) and titin
(Novocastra, Newcastle upon Tyne, United Kingdom).
Antigen retrieval, by boiling sections in a citrate-buffered
solution for 15 min, was performed on the sections for all
antibodies except myosin. Sections for myosin incubation
were proteolytic-digested with pepsin for 15 min.
All slides contained large transmural biopsies and were
examined completely by two to four investigators who
aimed for consensus. In these biopsies, all longitudinally
arranged cardiomyocytes were analyzed. In the case of IHD,
only surviving myocytes were studied; the necrotic area was
not taken into consideration. Besides providing a descrip-
tion of the histologic findings, a grading system was also
used for the immunohistochemical data, according to the
following scale: 1  almost all myocytes show a distorted
architecture with absence of cross-striation; 2  some
normal myocytes with cross-striation are present; most of
the myocytes are abnormal, however; 3  there are normal
myocytes with cross-striation, along with myocytes without
cross-striation, or myocytes without antigen staining over
the full length of the contractile fiber; 4  there are some
myocytes with a distorted architecture; most of the myocytes
are normal, however; and 5  almost all myocytes show a
normal architecture and cross-striation.
To test for inter- and intra-observer variabilities, grading
was repeated in half of the biopsies in a blinded manner, and
the kappa value of reliability was determined. The cardio-
myocytes’ cross-sectional area was measured on 3-m slides
stained with modified azan, making use of a Videoplan
morphometric program (Zeiss Kontron, Eching, Germany).
Thirty cells were measured perpendicular to the long axis;
oblique sections were excluded.
Control tissue. Before starting this study in patients with
an LVAD, we optimized our technique of tissue handling
and immunohistochemistry on all kinds of human myocar-
dial biopsies. This was mostly done to rule out the effects of
globally warm ischemia on the biopsies. As normal human
LV myocardial tissue is not available, atrial auricles obtained
at open heart surgery from patients without HF were used
for comparison.
Statistical analysis. Grading of the immunohistochemical
data was compared by using the paired Student t test. Inter-
and intra-observer variabilities were tested using kappa
analysis. A comparison between DCM and IHD was made
by using the unpaired Student t test. All data were calcu-
lated with SPSS version 8.0 for Windows. A p value 0.05
was considered significant.
Abbreviations and Acronyms
DCM  dilated cardiomyopathy
HF  heart failure
HTx  heart transplantation
IHD  ischemic heart disease
LV  left ventricle or ventricular
LVAD  left ventricular assist device
Table 1. Characteristics of Patients With an Implanted LVAD
Male (n) 12
Female (n) 2
Age (years) 32  12
Duration of HF* (months) 5.6  6.1
DCM/IHD (n) 8/6
LVEF (%) 13  5
CO (l/min) 3.4  1.2
MAP (mm Hg) 64  13
IABP/other support (n) 7
Duration of LVAD support (days) 213  135
*Time between onset of heart failure symptoms and implantation of LVAD (months).
CO  cardiac output; DCM  dilated cardiomyopathy; IABP  intra-aortic
balloon pump; IHD  ischemic heart disease; LVAD  left ventricular assist device;
LVEF  left ventricular ejection fraction; MAP  mean arterial pressure.
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RESULTS
Hematoxylin-eosin staining. At the time of LVAD im-
plantation, all myocardial biopsies showed widespread hy-
pertrophy of the myocytes, striking vacuolization and ab-
sence of normal cross-striation. Increased amounts of
lipofuscin and interstitial fibrosis were seen (Fig. 1A). After
LVAD support, at the time of HTx, the biopsies showed
less hypertrophy and vacuolization and some improvement
in cross-striation (Fig. 1B). None of the patients, however,
showed complete normalization. Interstitial fibrosis ap-
peared to increase in most patients. To rule out the effect of
implantation of the inflow cannula on this fibrosis, we also
examined longitudinal sections of the complete LV. These
biopsies showed that the interstitial fibrosis was diffusely
present throughout the whole LV. The inflow cannula only
caused a small local ring of dense fibrous tissue directly
around it. The widespread variation in myocyte histologic
features in both series of biopsies was remarkable, both at
LVAD implantation and HTx. Areas with almost normal
structure were neighbored by areas showing severe morpho-
logical disorganization.
Actin. The myocardial biopsies at the time of LVAD
implantation showed severe distortion of the actin-staining
pattern in nearly all myocytes, with barely any cross-
striation visible (Fig. 2A). Within some vacuoles, granular
material staining for actin was discerned.
At the time of HTx, some improvement in the actin
pattern was observed, with partial restoration of cross-
striation (Fig. 2B). Large areas, however, still demonstrated
an abnormal architecture.
Myosin. Remarkably, biopsies taken at the time of LVAD
implantation showed an almost normal myosin architecture
(Fig. 2C). In the vacuoles, no myosin-positive material was
discerned. In contrast to the partial improvement in actin
staining, myosin staining demonstrated a slight deteriora-
tion at the time of HTx (Fig. 2D).
Tropomyosin, troponin C and T and titin. The staining
pattern for these antibodies was comparable to that of actin
staining, but less pronounced. At the time of LVAD
implantation, some cross-striation was seen, but there were
also large areas with disorganization and a lack of contractile
material. Within individual cardiomyocytes, a wide variabil-
ity of the staining pattern was occasionally observed. At the
time of HTx, biopsies showed some improvement of cross-
striation, but areas with disorganization persisted. Within
each cardiomyocyte, the staining pattern appeared to be
more homogeneous after LVAD support than before it.
Between cardiomyocytes, however, the variability in the
staining pattern increased. This frequently resulted in alter-
nation of structurally normal myocytes with apparently
abnormal myocytes in the same contractile fiber—a peculiar
phenomenon not mentioned before in the published data
(Fig. 3).
The titin-staining pattern was comparable to that of the
other thin contractile filaments.
Grading of the contractile proteins. A clear pattern can
be delineated (Table 2, Fig. 4); the thin, contractile fila-
ments and titin demonstrated widespread disorganization at
the time of LVAD implantation and showed improvement
after support (p  0.004 for actin pre- vs. post-support). In
contrast, myosin, the main constituent of the thick contrac-
tile filament, displayed an almost normal morphology,
demonstrating a slight deterioration after LVAD support,
although not significant (p  0.058).
The inter- and intra-observer kappa values were 0.55 and
0.63, respectively, indicating fair agreement. Ischemic heart
disease showed a worse staining pattern of the thin contrac-
tile filaments at the time of LVAD implantation than
DCM (p  0.05 for actin, troponin C and titin). After
LVAD support, this difference disappeared.
There was no correlation between the grading of the
contractile elements in individual patients and the duration
of HF symptoms, the duration of LVAD support, the dose
Figure 1. Hematoxylin-eosin staining in left ventricular biopsies (original magnification50) before and after left ventricular assist device (LVAD) support.
(A) Before LVAD support, there were hypertrophic myocytes of varying nuclear sizes, with vacuolization and interstitial fibrosis. (B) After LVAD support,
the myocytes showed less hypertrophy and vacuolization, together with a decrease in myocyte size and an increase in interstitial fibrosis.
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and duration of catecholamine support before LVAD im-
plantation or the use of an intra-aortic balloon pump before
support.
Cross-sectional area of the cardiomyocytes. The cardio-
myocytes’ cross-sectional area decreased significantly, from
519  94 m2 before LVAD support to 319  53 m2
Figure 2. (A) Actin staining before left ventricular assist device (LVAD) support shows a severe distortion of the architecture and absence of cross-striation
in nearly all myocytes (grade 1). (B) Actin after LVAD support demonstrates some improvement in the staining pattern, with partial restoration of
cross-striation (grade 3). (C) Myosin before LVAD support displays a normal architecture (grade 5). (D) After LVAD support, some deterioration is
observed (grade 3). (original magnification 250).
Figure 3. Tropomyosin staining after left ventricular assist device (LVAD) support show the alternation of histochemical normal myocytes with abnormal
ones in the same contractile fiber. (original magnification 150).
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after support (p 0.001), a reduction of 36 19%. Normal
values in five control subjects showed a cross-sectional area
of 226  67 m2.
Normal atrial auricular tissue. The atrial cardiomyocytes
of patients undergoing coronary artery bypass graft surgery
showed a normal staining pattern of the contractile proteins
(Fig. 5).
DISCUSSION
In the present study, for the first time, to the best of our
knowledge, immunohistochemical data on contractile pro-
teins in cardiomyocytes are reported in patients with end-
stage HF treated with an LVAD. This study showed that
the myosin structure was preserved in patients with end-
stage HF before LVAD implantation. In contrast, the thin,
contractile filaments and titin demonstrated widespread
distortion of the normal staining pattern, with actin display-
ing the worst degradation. After LVAD support, a partial
improvement in morphology of the thin contractile fila-
ments and titin had occurred. In contrast, myosin demon-
strated a slight deterioration in histologic features. Further-
more, after LVAD support, the staining pattern within each
cardiomyocyte appeared to be more homogeneous. Between
different cardiomyocytes, however, the variability in the
staining pattern persisted, leading sometimes to the alter-
nation of apparently abnormal myocytes with normal ones
in the same contractile fiber. This may affect cardiac
contractility in a negative way and may also affect the spread
of the electrical impulse, creating a condition for re-entry.
Finally, a significant decrease in the cardiomyocytes’
cross-sectional area after LVAD support was demonstrated,
although normalization was not complete.
The role of immunohistochemistry in HF. Immuno-
histochemic studies on myocardial tissue in chronic HF are
scarce and comprise mainly hearts with DCM (2,19,20).
With respect to the thin contractile filaments and titin, our
results correspond to these studies. In contrast to the study
reported by Hein et al. (19), the myosin pattern in our
patients with end-stage HF was remarkably preserved. This
relative sparing of myosin, however, has been demonstrated
before in a study of dogs in whom regional ischemia was
induced by ligation of the left anterior descending coronary
artery (21).
Recovery of myocyte function. Despite persistence of
widespread areas with a distorted myocyte architecture, as
Table 2. Grading Scale of the Contractile Proteins*
LVAD
Implantation
Heart
Transplantation
Actin
DCM 1.6  0.7 2.6  1.4
IHD 1.0  0.0† 2.8  1.3
All 1.4  0.6 2.7  1.3 (p  0.004)
Myosin
DCM 4.8  0.5 3.4  1.6
IHD 4.3  0.8 3.8  1.6
All 4.6  0.7 3.6  1.6 (p  0.058)
Tropomyosin
DCM 2.6  0.9 3.3  1.3
IHD 1.8  1.0 3.2  1.2
All 2.3  1.0 3.2  1.2 (p  0.021)
Troponin C
DCM 2.5  0.8 3.0  0.9
IHD 1.5  0.8† 3.7  0.8
All 2.1  0.9 3.3  0.9 (p  0.004)
Troponin T
DCM 2.0  0.9 2.6  1.2
IHD 2.2  1.6 3.5  0.8
All 2.1  1.2 3.0  1.1 (p  0.048)
Titin
DCM 2.3  0.5 3.3  1.0
IHD 1.7  0.5† 3.0  0.6
All 2.0  0.6 3.1  0.9 (p  0.001)
Data are presented as the mean value  SD. *For an explanation of the grading scale,
see text. †p  0.05 for IHD versus DCM, at the time of LVAD implantation.
Abbreviations as in Table 1.
Figure 4. Grading of the contractile proteins in myocytes before and after
left ventricular assist device (LVAD) support. Myosin staining showed
some deterioration (grade 4.6 before LVAD implantation vs. 3.6 after
LVAD support; p 0.058). In contrast, the contractile proteins of the thin
filaments and titin showed improvement (grade 1.4 for actin before LVAD
implantation vs. 2.7 after LVAD support; p  0.004). Severe structural
myocyte damage persisted, despite a period of LVAD support of 213 
135 days. HTx  heart transplantation; Trop  troponin.
Figure 5. Human atrial cardiomyocytes show normal cross-striation (actin
staining, grade 5; original magnification 250).
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shown in this study, LVAD implantation leads to an
impressive improvement in the hemodynamic condition in
our patients (18), as well as in those reported in other
studies. The decrease in cardiomyocyte size is in accordance
with other studies (17,22,23). Furthermore, LVAD support
results in a decrease in cardiac dimensions (4–6,17,24), an
improvement of myocyte (7,25,26) and mitochondrial func-
tion (27,28), an improvement of neurohormonal activation
(12,13,17), an increase in beta-receptor density (29) and
disappearance of antibodies against beta-receptors (9), as
well as a decrease in serum interleukin (IL)-6 and IL-8 (30).
Recently, a decreased susceptibility to apoptosis (31) and a
reduction in tumor necrosis factor-alpha activity in nonisch-
emic cardiomyocytes after support were shown (32). Histo-
logic studies after LVAD support showed a reduction of
wavy fibers, contraction band necrosis and myocytolysis,
accompanied by an increase in myocardial fibrosis (4–
6,8,9,16,17), although recently, a reduction in the collagen
content was also reported after LVAD support (23).
These alterations, however, probably resulted from un-
loading of the heart with consequent circulatory recovery
and may not be specific for LVAD support at all. Medical
therapy (e.g., angiotensin-converting enzyme inhibitors and
beta-adrenergic blockers) also improves the circulatory sta-
tus and slows deterioration of the failing heart, a benefit that
is partly due to inhibition of remodeling (14,33). Further-
more, spontaneous improvement in LV function is well
known in myocarditis and in peripartum cardiomyopathy
and was also reported in 27% of patients with recent-onset
DCM (34). This may partly explain the number of patients
being weaned from LVAD support in some studies. It is
evident that in these situations, an LVAD can play an
important role in keeping a patient alive and gaining time
for cardiac improvement. At present, however, there is no
evidence available that LVAD support can be a permanent
cure for patients with HF (15). The extent of myocardial
recovery after LVAD support is highly variable (11,35,36),
and there are conflicting data on the amount of fibrosis after
support. The increased fibrosis demonstrated in our study
and by others (4,6,37) will have a negative impact on systolic
and diastolic cardiac function, limiting the chance for
complete recovery. Furthermore, the inadequate presence of
titin after LVAD support, as seen in our study, can hamper
the formation of new sarcomeres, because titin is necessary
as a template for the organization of newly synthesized
myosin and actin filaments (19).
A new and intriguing strategy that combines mechanical
and intensive pharmacologic therapy to promote reverse
remodeling and uses clenbuterol to induce physiologic
hypertrophy has been suggested—the Harefield approach
(38,39). This requires further studies to determine the
long-term efficacy and to elucidate the concepts of reverse
remodeling (39).
Study limitations. In principle, abnormalities observed in
cardiac biopsies could partly be caused by global warm
ischemia of cardiac tissue after obtaining the biopsies.
Diseased human hearts are extremely susceptible to the
effects of ischemia, particularly the contractile proteins (20).
Therefore, we optimized our tissue handling so that 90% of
the biopsies were fixed within 10 min. The normal archi-
tecture of the myosin pattern in the patients with HF argues
against global ischemia as a potential mechanism in our
findings, because in the study of Hein et al. (20), it was
shown that all contractile proteins are equally sensitive to
the effect of global ischemia. Furthermore, our control
biopsies were also exposed to the potential effect of global
ischemia, but showed a normal staining pattern of the
contractile proteins. Most importantly, in this study, every
patient was its own control. The improvement in the
staining pattern of all thin contractile proteins and titin in
the biopsies after LVAD support, which are handled in the
same way as before LVAD placement, is a strong argument
against the effects of global warm ischemia.
Another problem is that biopsies may not be representa-
tive of the whole heart. This problem is overcome, in the
greater part in this study, by the quantity of available tissue
(1- to 3-cm biopsies).
All of our patients had end-stage HF. It cannot be ruled
out that patients with less severe forms of HF may actually
show more recovery of myocyte histologic features after
LVAD support.
The rather long duration of LVAD support in this study
may mean that the optimal period of recovery has been
exceeded, because some clinical and animal studies suggest
that recovery is complete within a couple of weeks
(11,26,40).
In our patients with LVAD support, all cardiac medica-
tions were stopped. It is not known to what extent this could
have influenced recovery; this will be an area for future
research.
Conclusions. Despite impressive hemodynamic recovery, a
decrease in the cardiomyocytes’ cross-sectional area and an
improvement in the staining pattern of the thin contractile
elements and titin, our findings endorse the persistence of
severe structural myocyte damage after a long duration of
LVAD support (213  135 days). Our findings do not
support complete recovery of myocyte histologic features
after a period of unloading of the heart by LVAD support.
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